Navigation Links
Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Date:4/25/2013

EAST SETAUKET, N.Y., April 25, 2013 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT), reported the start of a Phase I trial to determine the appropriate dose of its potentially first-in-class, anticancer compound, LB-100, when given alone and then when given in combination with docetaxel (Taxotere®). Details of the trial underway at an NCI-designated Comprehensive Cancer Center are available in the clinical trials registry: http://clinicaltrials.gov/show/NCT01837667.

Dr. John Kovach , the founder of Lixte said that "LB-100 inhibits an enzyme necessary for cancer cells to recover from damage to DNA. In mouse model systems of human cancers, LB-100 potentiates the activity of widely used anti-cancer regimens that exert their therapeutic benefit by damaging DNA without apparent increases in their toxicity. We hope the same benefit of the combination of LB-100 and known anti-cancer drugs will be seen in patients.  In the present trial, LB-100 will be partnered with the versatile drug, docetaxel.  As a single agent, docetaxel is the treatment of choice for several common cancers after failure of first-line therapy. Enhancement of the therapeutic benefit of docetaxel for these cancers is the initial goal in the clinical development of our novel DNA-repair disrupter."

About Lixte Biotechnology Holdings, Inc.

Lixte is a drug discovery company, using biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte is engaged primarily in development of improved treatments for cancer.

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Annual Report on Form 10K for December 31, 2012.

For additional information, please see:  www.lixte.com


'/>"/>
SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
2. Puma Biotechnology Announces Completion of Private Placement
3. Animal Biotechnology - Technologies, Markets and Companies
4. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
5. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
6. JumpStart Invests $250,000 in Milo Biotechnology
7. Global Biotechnology Industry
8. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
9. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
10. Global Biotechnology Instrumentation Industry
11. Choose New Jersey, Inc. to Tout New Jerseys Life Sciences Hub At Worlds Largest Biotechnology Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Genetics Center (RGC), U.K. Biobank and GSK to generate genetic ... Biobank resource. The initiative will enable researchers to gain valuable ... for a wide range of serious and life threatening diseases. ... Genetic ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017 ... announced that it has eclipsed the 130 million covered ... Cross Blue Shield of Texas . ... stages, the Company continues to enjoy strong payor acceptance ... of its clinical programs and genetic counseling, its industry-leading ...
(Date:3/22/2017)... -- MarketNewsUpdates.com News Commentary  ... The traditional ways to treat ... of late due to the rise of the opioid crisis. ... impact on patient,s quality of life as Biotech and Pharma ... forms of opioid formulations that prevent abuse. Biotech and Pharma ...
(Date:3/22/2017)... ... ... Premier executive recruitment firm, Slone Partners, is proud to have been named a Top ... Hunt Scanlon Media is one of the most respected life science publications in the ... sector. , “It is a great honor for Slone Partners to be part of ...
Breaking Biology Technology:
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , ... Well Made Simple," and 23andMe , the leading ... better food choices.  Zipongo can now provide customers with ... preferences, health goals and biometrics, but also genetic markers ... choices. Zipongo,s personalized food decision support platform ...
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
(Date:3/1/2017)...  Aware, Inc. (NASDAQ: AWRE), a leading supplier of ... Moberg has resigned, effective March 3, 2017, as ... and Treasurer of Aware citing a desire to retire.  ... of the Board of Directors of Aware. ... and co-President, General Counsel has been named Chief Executive ...
Breaking Biology News(10 mins):